Kornimate/medical-research-clean huggingface dataset:
investigation of the biomarker copeptin in patients with acute myocardial infarction

Conditions: Acute Coronary Syndromes

Summary: while troponin is not detectable until several hours after an acute myocardial infarction (ami), copeptin is expected to be elevated very early after an ami. a combination of both markers for the diagnosis of ami early after the event is therefore expected to be advantageous.

in patients with symptoms suggestive of acute coronary syndrome (acs) such as chest pain or pressure, shortness of breath, diaphoresis, and nausea, detection of a rise and/or fall of troponin with at least one value above the 99th percentile of the upper reference limit is essential to the diagnosis of acute myocardial infarction (ami). however, current troponin testing has limitations, including antibody specificity, assay imprecision, lack of standardization and a relatively late increase in the circulating troponin level after the onset of ischemia. studies have shown a low diagnostic sensitivity of troponins when measured early (\<6 hours) after symptom onset. although there are some more sensitive troponin assays with a coefficient of variation (cv)10% at the 99th percentile of a normal reference population, most troponin assays have an imprecision cv of around 20% at the 99th percentile of the reference population. the early insensitivity of troponin results in an unmet need in the clinical evaluation of patients presenting with suspected acs and ami. copeptin may improve early ami diagnostic sensitivity because of a number of unique characteristics. * copeptin levels are elevated at presentation in patients with ami compared to patients with other presentations. * copeptin levels are elevated in patients with ami even when troponin levels were not elevated at the time of initial presentation. * thus, a combination of troponin and copeptin levels at presentation may result in a more accurate diagnosis of acute ami than troponin alone. * copeptin levels drop 1 day after an ami.

Eligibility criteria:
inclusion criteria: * the subject must be 18 years of age or older. * the subject must present to the emergency department with symptoms consistent with acute coronary syndromes (e.g., chest discomfort/pain, squeezing/fullness in the chest, pain radiating to left or both arms, jaw pain, pain in the back/neck/stomach, shortness of breath, cold sweat, nausea/vomiting, lightheadedness). * the subject must present to the emergency department within 6 hours of the onset of the most recent symptoms that prompted the subject to seek medical attention in the emergency department. * the patient agrees to abide by all aspects of the protocol, including all telephone follow-up. exclusion criteria: * the patient is unable to provide consent or understand the consent form. * the acs symptoms are clearly not the result of acs (i.e., penetrating wounds, crush injury, etc.)

Keywords: acute myocardial infarction st-segment elevation myocardial infarction stemi non-st-segment elevation myocardial infarction nstemi unstable angina unstable angina pectoris ua uap
targeted fluorescence imaging in amd

Conditions: Age-Related Macular Degeneration; NAMD

Summary: rationale: to track performance of intravitreal distribution of anti-vegf-a (bevazicumab-800cw) and provide information about neovascularization and inflammation in age-related macular degeneration (amd), thereby predicting progression and optimizing treatment objective: to determine the safety and feasibility of fluorescence imaging of the eye with the fluorescent tracer bevacizumab-800cw for identification amd with scanning laser angiography study design: a non-randomized, non-blinded, prospective, single-center feasibility study. study population: patients group: patients with naïve wet amd and wet amd aged \>60 years old with current treatment of anti-vegf intravitreal. control group: patients with naïve wet amd and wet amd aged \>60 years old with current treatment of anti-vegf intravitreal intervention (if applicable): intravenous injection of bevacizumab-800cw in the patient group. main study parameters/endpoints: safety and feasibility of the intravenous tracer bevacizumab-800cw in patients with naïve wet amd and wet amd by observing the uptake in retinal, choroid and neovascular tissue. nature and extent of the burden and risks associated with participation, benefit and group relatedness: no risk described in other (running) studies on intravenous injection with bevacizumab-800 cw. patients need to come back 48-96 hours after injection and the eye measurements take about half an hour longer. there is no benefit with participation.


Eligibility criteria:
inclusion criteria: * patients with either naïve wet amd or wet amd receiving standard care of anti-vegf therapy * aged \>60 years old optional: patients already included in fluorescence study which involves bevacizumab-800cw exclusion criteria: * eye pathology interfering with retinal imaging; * patients with psychological diseases or medical issues who are not able to sign informed consent form; * concurrent uncontrolled medical conditions; * received a different investigational drug within 30 days prior to the dose of bevacizumab-800cw; * history of infusion reactions to bevacizumab or other monoclonal antibody.

Keywords: fluorescence, ophthalmology, bevacizumab-800cw, namd
prevent cardiokids

Conditions: Cardiovascular Disease

Summary: the aim of prevent cardiokids is to evaluate to what extend disturbed vascular function markers are already present in children of different weight categories and whether these are age dependent. also differences - and relationships - between vascular function measurements and plasma biomarkers between lean and overweight/obese children will be compared.

the aim of prevent cardiokids is to evaluate to what extend disturbed vascular function markers are already present in children of different weight categories and whether these are age dependent. also differences - and relationships - between vascular function measurements and plasma biomarkers between lean and overweight/obese children will be compared.the primary endpoint is to examine the difference in micro- and macro-vasculature characteristics in children with different weight classifications (lean; overweight; obese; extreme obese; morbid obese). secondary endpoints are differences in lipoprotein profiles, pro-inflammatory and oral glucose tolerance profiles between different age groups, between lean and overweight/obese children and in relation with the measured micro- and macro-vasculature characteristics

Eligibility criteria:
inclusion criteria: * participation in the coach program * aged between 6 and 18 years (at time of inclusion) * overweight or obesity according to iotf criteria in order to be eligible to participate in the control group, a subject must meet all of the following criteria: * aged between 6 and 18 years * normal weight according to the iotf criteria * undergo surgery for elective reasons exclusion criteria: * retarded children * children suffering from: * inflammatory diseases: auto-immune diseases, inflammatory bowel diseases, hepatitis, dermatitis, nephritis, pancreatitis, gastro-enteritis, vasculitis, salpingitis, arthritis, osteomyelitis, myositis, ear-nose-throat infections * allergic diseases: asthma, eczema, hay fever, food allergies * oncologic diseases * cystic fibrosis * type 1 diabetes mellitus * congenital metabolic diseases * malnourished children
telemedicine versus traditional treatment of muscle tension dysphonia

Conditions: Muscle Tension Dysphonia

Summary: the purpose of this research is to determine whether treatment of voice disorders can be provided just as effectively using telemedicine as it can using on-site, traditional therapy. an exercise protocol for improving airflow with voicing has been demonstrated to be effective in a prior uams investigation (protocol 107454). these exercises are used as part of the normal clinic routine at uams working with individuals with voice problems. the three exercises used are: gargling with and without voicing; cup bubble blowing with and without voicing; and, stretch and flow exercises, which involves the use of a piece of tissue to provide visual biofeedback on the ability to use proper airflow with voicing. the purpose of the exercises is to increase airflow and breathiness in the voice and reduce muscle tension. in addition, patients will be taught to use a "confidential voice" or gentle voice during speaking. the investigators voice patients come from all over the state and many cannot return for regular treatment. developing a way to provide treatment to them closer to home could greatly improve quality of care and quality of life. twenty participants will participate for 12 sessions each. all participants will be evaluated at uams before and after treatment as part of standard care and will, upon consent, be randomized to receive treatment via telemedicine at an ahec site or at uams medical center. homework will be provided along with log sheets. results of airflow measures using an airflow-recording device (viasys, kay/pentax) pre- and post treatment will determine whether telemedicine results are equal to results of traditional, on-site treatment. the investigators hypothesize that results from treatment using telemedicine will be equivalent to results for onsite, traditional treatment.


Eligibility criteria:
inclusion criteria: * primary or secondary muscle tension dysphonia exclusion criteria: * head and neck cancer * spasmodic dysphonia * tremor * respiratory compromise * dysphagia

Keywords: voice muscle tension dysphonia hyperfunction treatment
nowdx test for the diagnosis of syphilis

Conditions: Syphilis Infection; Treponema Pallidum Infection

Summary: this study is designed to compare the performance of the nowdx syphilis test to a currently marketed device. the intent is to show the rapid test device is comparable to the currently marketed device. the nowdx syphilis test is intended for qualitatively detecting the presence or absence of human antibodies to syphilis in human whole blood to aid in the diagnosis of infection caused by treponema pallidum.

the objective of this study is to establish the performance characteristics of the nowdx syphilis test based on comparison to the biorad bioplex 2200 series syphilis total (igg/igm), wampole impact rpr test kit, and to the serodia treponema pallidum particle agglutination assay (tp-pa). the external clinical study along with in-house analytical studies will demonstrate the efficacy of the nowdx syphilis test as an aid in the diagnosis of syphilis infection for at home testing and point of care testing sites. participants will self test and be tested by clinical laboratory improvement amendments (clia) waived operators with the nowdx syphilis test at independent sites in wa, az, and nv. two sample types will be tested with the nowdx syphilis test for each participant: fingerstick whole blood and venous whole blood. sera from each participant will be tested at an independent reference laboratory. the nowdx syphilis test will be evaluated in diverse populations of sexually active persons who self-select for syphilis testing and expectant mothers.

Eligibility criteria:
* sexually active persons who self-select for syphilis testing * n=840 participants; \~280 per study site * inclusion criteria: - sexually active persons 18-64 years old * exclusion criteria: * persons \ 64 years old; * persons with limited or no reading skills; * persons who previously participated in a nowdx study * expectant mothers * n=222 participants; \~74 per study site * inclusion criteria: - expectant mothers ≥18 years old * exclusion criteria: * persons \<18 years old; * persons with limited or no reading skills; * persons who previously participated in a nowdx study * lay users * n=48 participants; \~16 per study site * inclusion criteria: * persons 18-64 years old; * -½ high risk sexual behavior; ½ low risk sexual behavior * exclusion criteria: * persons \ 64 years old; * persons with limited or no reading skills; * persons who previously participated in a nowdx study

Keywords: syphilis treponema pallidum
prednisone for decompensated congestive heart failure

Conditions: Heart Failure, Congestive

Summary: we designed this, randomized, double-blind, placebo-controlled trial to determine the clinical efficacy of chronic administration of prednisone on renal function and clinical status when added to standard care.

studies showed that glucocorticoids could specifically dilate renal vessel, increase in gfr, and regulate synthesis and release of atrial natriuretic peptide (anp), upregulate anp receptors on vascular endothelial cells, leading to significant diuresis and natriuresis. adding glucocorticoids to standard care may potentiate the diuretic and natriuretic effects of diuretics and improve renal function, thus improve the clinical outcomes.

Eligibility criteria:
inclusion criteria: * hospitalized with primary diagnosis of chf * patients with normal cortical function * lvef \<40% * significant fluid overload, defined as ≥ 2 of the following * enlarged liver or ascites * peripheral or sacral edema ( ≥ 2+) * jugular venous distention ≥ 10 cm * pulmonary rales, pleural effusion on chest x-ray or orthopnea exclusion criteria: * severe stenotic valvular disease * serum creatinine \> 4 mg/dl * patient refusal * any signs of infection or any condition that would contraindicate an glucocorticoids use * poor controlled hypertension * poor controlled diabetes mellitus * active myocarditis * malignancy or other terminal illness

Keywords: decompensated heart failure prednisone diuretics diuresis
the effect of nitric oxide on spatial working memory in patients with schizophrenia - pilot study

Conditions: Schizophrenia

Summary: spatial working memory (ability to remember where objects are in space) is impaired in patients with schizophrenia. it is thought that this impairment occurs due to problems with the chemical messenger (neurotransmitter), glutamate, and the n-methyl-d-aspartate (nmda) glutamate receptor, particularly in the hippocampal brain region. nmda receptor activation leads to increases in the release of the second messenger nitric oxide. impaired nmda receptor function would therefore be predicted to lead to reductions in nitric oxide production. recent work suggests that a drug, sodium nitroprusside, which releases nitric oxide, enhances some aspects of cognition in schizophrenia (specifically related to negative symptoms). in this study, the investigators will test the hypothesis that sodium nitroprusside improves spatial working memory in patients with schizophrenia. 15 patients will receive sodium nitroprusside, and 15 will receive a nonactive compound (placebo). their performance on a spatial working memory task will be tested before and after administration of sodium nitroprusside or placebo.


Eligibility criteria:
inclusion criteria: patients with a diagnosis of schizophrenia or schizoaffective disorder, currently experiencing an exacerbation of symptoms (a score \> 20 for panss-positive subscale), currently taking antipsychotics and who have given informed consent to participate. exclusion criteria: history of hypertension or current resting systolic blood pressure greater than 140 mmhg or diastolic blood pressure greater than 90 mmhg. relevant medical illness (renal, hepatic, cardiac), prior history of intolerance to sodium nitroprusside, presence of a seizure disorder, any change in psychotropic medication in previous 6 weeks, diagnosis of substance abuse, pregnancy (as determined by urine test) or breastfeeding.

Keywords: nitric oxide sodium nitroprusside spatial working memory psychosis schizophrenia
in vitro follicle activation in patient with premature ovarian failure under 36 years old

Conditions: Activation of Primordial Follicles

Summary: this is a clinical trial that the investigators aim to validate in-vitro activation (iva) treatment protocol, which was previously defined by kazuhiro kawamura (md) and aaron hsueh (phd), in turkish patient with premature ovarian insufficiency (poi) under age 36.

the objectives of the study is as following; * validation of the previously defined in-vitro activation protocol approach in turkish patients under 36 years old with premature ovarian insufficiency (poi). * giving an opportunity to young poi patient in turkey for having genetically own baby. * primary outcome measure would be live birth. * for activation of primordial follicles, phosphatase and tensin homolog (pten) inhibitor and protein kinase b (akt) stimulator will be used.

Eligibility criteria:
inclusion criteria: * patient with poi * short amenorrhea period (1 - 2 years) exclusion criteria: * having been treated with chemotherapy and/or radiotherapy; * having been diagnosed with advanced stage of endometriosis (endometriomas) * having been diagnosed with the chronic diseases such as diabetes, cardiac failure, kidney insufficiency, morbid obesity etc.. * presence of chromosomal abnormality (turner, fragile-x etc.) * previous multiple laparotomies * menopause \>10 years * accompanied azoospermia
selective sentinella lymph node biopsy with indocyanine green in patients with breast cancer

Conditions: Breast Cancer

Summary: the current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. the objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.

in the operating room 1 ml of indocyaninge grenn will be injectec periareolar . after 5 minutes the lymph node will be detected and extracted. the comparison between the lymph nodes detected with technetium 99 and indocyanine green will be analysed.

Eligibility criteria:
inclusion criteria: * patients \>18 years of age with breast cancer who are candidates for sentinel lymph node detection will be included. * n0 patients or patients who have undergone target axillary detection with good response exclusion criteria: * lymphadenectomy

Keywords: lymph node detection indocyanine green breast cancer
value of inguinal exploration for impalpable testes

Conditions: Undescended Testis; Inguinal; Testicle

Summary: * to determine the percentage of children with impalpable testis who benefit from inguinal exploration after laparoscopic identification of cord structures entering the inguinal canal. * to determine the factors predicting the presence of inguinal testis in the previously mentioned children.

the undescended testis represents one of the most common disorders of childhood. the most useful classification of undescended testes is distinguishing palpable and non-palpable tests, and the location and presence of the tests decide clinical management. approximately 80% of all undescended tests are palpable and the other 20% are impalpable. among the 20% of non-palpable testes, 50-60% are intra-abdominal, canalicular, or peeping (right inside the internal inguinal ring). the remaining 20% are absent and 30% are atrophic or rudimentary. diagnostic laparoscopy is the most useful modality for assessing nonpalpable testicles. the four most important structures to identify at laparoscopy are the testis, the testicular vessels, the vase deferens, and the patency of the processus vaginalis. the possible anatomical findings include spermatic vessels entering the inguinal canal (40%), an intra-abdominal (40%) or peeping (10%) testis, or blind-ending spermatic vessels confirming vanishing testis (10%). it permits the identification of three surgical scenarios that will lead to different courses of action: 1. blind-ending vessels, which indicate a vanishing intra-abdominal testis, and no further exploration is necessary (10%) 2. testicular vessels and vas entering the inguinal canal through the internal inguinal ring (34%).inguinal exploration may find a testicular nubbin either in the inguinal region or in the scrotum, which may or may not be removed; or a healthy, palpable, undescended testicle amenable to standard orchidopexy. 3. peeping (11%) or intra-abdominal tests (37%), which will require either an open or a laparoscopic approach. although rozanski et al. reported the first case of intratubular germ cell neoplasia originating from a testicular remnant, the necessity of removing nubbins is controversial.

Eligibility criteria:
inclusion criteria: * age 6m-12y * impalpable tests (unilateral or bilateral) * laparoscopy: cord structures entering the inguinal canal. exclusion criteria: * patient refusing participation in the study. * any contraindication to laparoscopy * laparoscopy: cord structures passing through an open inguinal canal through which the laparoscopy could be advanced and visualize the tests. * disorders of sexual differentiation. * children whose tests became palpable under anesthesia and those with a history of previous inguinal canal exploration (hydrocele or hernia repair) or orchidopexy.
dance-therapy and chronic pain

Conditions: Chronic Pain; Complex Regional Pain Syndromes; Tension-Type Headache

Summary: pain, when it becomes chronic, can be a threat to patients and it is very common to observe a fear of pain and a fear of movement (kinesiophobia). avoidance of movement due to fear of pain can lead to a deterioration of body image. non-medicinal therapies are essential to correct this fear and movement avoidance behavior, to decrease "catastrophic" judgments and thus anxiety. the use of art-therapy in the accompaniment of patients with pain has shown, in particular, decreases in the intensity of pain, the level of anxiety, an improvement in stress, mood and overall psychological state. however, according to the current literature, it appears that 1) this technique is rarely used in children or adolescents, for whom non-medicinal therapies are fundamental, and 2) in the case of chronic pain, the form of art used is very rarely related to the body (most often painting, drawing, music...). in this project, investigators propose to set up and test the potential benefit of art-therapy sessions related to the body, namely dance-therapy, in adolescents and young adults suffering from chronic pain.


Eligibility criteria:
inclusion criteria: * patients aged 12 to 20 years, girls or boys, with either complex regional pain syndrome (crps) or chronic tension-type headache (ctth). * diagnosis of crps or chronic ctth made in a pain management center * patients followed in a pain management center (to ensure that patients entering the protocol have pain that is not relieved by conventional treatments) * patients who have given written consent for adults or whose parents have given consent for minors * patients who are affiliated with or benefit from a social security system. exclusion criteria: * patients with headaches other than ctth * patients with other neurological or psychological disorders * patients with psychiatric illnesses * patients with chronic pain conditions other than crps or ctth * patients with chronic infectious, metabolic, cancerous, autoimmune diseases. * patients whose motor limitations are not related to the diagnosis of crps or ctth (e.g. cerebral palsy, spinal cord injury...) * non-communicating patients including deaf and hard of hearing patients * patients or parents who do not speak or read french * pregnant women * dance or yoga professionals (dance or yoga teachers or those studying to become teachers)

Keywords: dance-therapy chronic pain complex regional pain syndrome tension type headache adolescents
the therapeutic effects of continuous theta burst stimulation in autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the investigator would like to investigate the impact of theta burst stimulation over left dorsolateral prefrontal cortex in autism spectrum disorder


Eligibility criteria:
inclusion criteria: * autism spectrum disorder, confirmed by ados exclusion criteria: * current and past systemic disease * current and past major psychiatric disorders including schizophrenia, bipolar affective disorder and major depressive disorder * current and past brain injuries * intelligence \< 70 * seizure history * pregnant